ClinicalTrials.gg
RecruitingNCT05028062Updated Jan 20, 2026

Naltrexone in AUD Reward Drinkers

A Phase 4 interventional study of XR-NTX 380 mg, intramuscular injection and Medical Management in Alcohol Use Disorder and Alcoholism, sponsored by University of Pennsylvania. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by University of Pennsylvania · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Alcoholism by University of Pennsylvania — 7 open to participants now, 9 under way, 5 of them phase 3. Alcoholism · University of Pennsylvania.

Planned enrollment
14th of 28
60 · median 60
Started
2022
the only one that year
Phase 4
5 of 28
1 open now
Registered
22nd of 28
by date

Among the 28 studies in Alcoholism by University of Pennsylvania, this one is the 14th largest by planned enrollment, is the only one that started in 2022, is one of 5 in phase 4, and was the 22nd registered.

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

7 of the 28 studies in Alcoholism by University of Pennsylvania are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Alcoholism by University of Pennsylvania, or all of them as a file.
02

Study summary

This study is a phase IV, two-arm, randomized, double-blind, placebo-controlled study to assess whether individuals identified as primarily reward drinkers are significantly more likely to reduce heavy drinking if they receive XR-NTX than a matching placebo injection.

Study subjects will receive monthly injections of long-acting injectable naltrexone 380 mg (4 mL) or matching placebo. All subjects will also receive 4 sessions of Medical Management (MM). Post-treatment follow-up visits will be conducted at 4 weeks after the scheduled completion of treatment.

Read the detailed description

Study eligibility is determined at an initial screening visit, which can be completed in a single day or divided over multiple days. Portions of the screening may occur by telephone or video conference. Participants are asked not to drink before this and at all study visits. At all study visits, study staff will check breath alcohol level using a breathalyzer. If the breath alcohol level is greater than 0.02% (which can result from a single standard drink), participants may not be able to complete the visit.

Screening Visit: The screening visit will determine whether the study is a good fit for participants. It take about three hours to complete.

  • Participants will be asked to show legal photo ID and undergo a breathalyzer test to ensure that the breath alcohol level is below 0.02% to complete this visit. A reading test wil be given to evaluate participant's ability to understand the consent form and study assessment questionnaires.
  • Once the informed consent is complete a study clinician will complete a medical history and perform a physical examination. Study staff will draw approximately 3 tablespoons of blood for standard laboratory tests. Participants will also be asked to provide a urine sample to conduct a urinalysis, drug screen, and a urine pregnancy test (only for for women of childbearing potential--i.e., who have not had a hysterectomy, bilateral removal of the ovaries, or a tubal ligation or is less than two years postmenopausal). We will not include women who are pregnant, breast-feeding.
  • Eligible participants will be required to provide the names and contact information of one or two people (trusted friends or family members) who may serve as additional contacts to assist staff with locating participants for safety or other study-related reasons.
  • Participants will be asked to complete 4 assessments of about psychological health and alcohol and drug use history.

First Study Drug Visit (Week 1): Staff will contact participants within 1 week after completing the screening visit to inform eligibility status and schedule the next study visit.

  • This visit will take approximately one and one-half hours to complete.
  • Participants will be asked to complete a breathalyzer test and study staff will measure weight and vital signs (blood pressure and heart rate).
  • Woman of childbearing potential, will be asked to provide a urine sample for a pregnancy test.
  • Participants will be asked to complete 11 assessments about psychological health and alcohol and drug use history.
  • Staff will instruct participants how to use the interactive voice response (IVR) system via telephone. During the 8 weeks of the study, participants will be asked to call a toll-free phone number each day, between 5:00 and 8:00 p.m. to connect to the system. Access to the system via a touch-tone phone requires a study ID and a password. The system has prompts to answer questions about feelings and use of alcohol on the day of the call and the preceding day. It takes about 5 to 8 minutes to complete the daily interview. The IVR system will provide a reminder if a call has not been completed by 8:15 p.m.
  • The first brief counseling session will last about 45 minutes. The study nurse will discuss a treatment goal either to drink less or become completely abstinent. The nurse will also encourage participants to consider ways to reduce or stop drinking, based upon the treatment goal.
  • Participants will be assigned to receive an injection of study medication administered by the nurse, which will be either XR-NTX or placebo (an inactive substance). The decision as to which medication received will be random, like a flip of a coin. The XR-NTX or placebo will look the same. Neither participants nor any of the study personnel will know which medication is received. In an emergency, though, the study staff in charge of the study medication can be contacted for that information.
  • At each visit, study staff will ask about any side effects or other adverse events.

Biweekly Visits (Weeks 2, 4, and 6): At each biweekly visit:

  • The staff will check breath alcohol concentration (Breathalyzer), weight, and vital signs and ask about any side effects or other adverse events that were experienced.
  • Participants will asked to complete 6 assessments about psychological health and alcohol and drug use history. These should take about 20 minutes to answer.
  • Participants will receive brief counseling from the study clinician, which will last about 20 minutes.
  • At week 4, woman of childbearing potential, will have another urine pregnancy test. If the urine permanency test is positive, staff will discontinue the medication and the participant will be referred to an obstetrician for care.
  • At week 4 the study nurse will give the second injection of XR-NTX or a placebo (an inactive substance)
  • Participants will continue to call and complete the toll-free IVR number nightly.

    4. Endpoint Visit (Week 8): At this visit:

  • The staff will measure breath alcohol concentration (Breathalyzer), weight, and vital signs and asked about any side effects or other adverse events that may have experienced.
  • The study staff will ask you to complete 11 assessments about your psychological health and your alcohol and drug use history. These should take about 45 minutes to complete.
  • Study staff will draw 1 tablespoonful of blood for lab tests.
  • Participants will receive brief counseling from the study clinician, which will last about 20 minutes.

Follow-up Visits (4 weeks after endpoint visit): At the follow-up visit (which will take about one hour), the study staff will:

  • Check breath alcohol concentration (Breathalyzer), weight and vital signs.
  • Draw 1 tablespoonful of blood for lab tests.
  • Participants will be asked to complete 9 assessments about psychological health and alcohol and drug use history.
  • Once participants have completed the study, they will have an option to receive a letter to inform them whether they received XR-NTX or placebo medication.

Early Termination Visit

  • Participants who choose to withdraw from the study before participation is complete will be asked to return to the research center for a visit to allow staff to administer the end-of-study procedures.
03

Conditions studied

  • Alcohol Use Disorder
  • Alcoholism

Browse trials for

Keywords

  • XR-NTX
  • Naltrexone
  • Alcohol
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-65 years old
  • Willing to provide signed, and commit to completing the study procedures
  • Able to read at an 8th grade or higher level
  • Current diagnosis of AUD
  • Reports consuming 24+ standard drinks (men) or 18+ standard drinks (women) weekly on average over the month prior to consent
  • Expresses a desire to reduce or stop drinking and a willingness to receive two injections of study medication over 8 weeks of treatment.
  • Either a reward drinker [i.e., an individual with a score of 19 or greater on the reward subscale and less than or equal to 18 on the relief subscale of the Inventory of Drinking Situations (IDS)] or a relief drinker (i.e., an individual with a score of 21 or greater on the relief subscale and less than or equal to 18 on the reward subscale of the IDS).
  • Has a stable address in the local area; not planning to move; has documents for an ID check
  • Women of (i.e., who have not had a hysterectomy, bilateral oophorectomy, tubal ligation or are less than two years ): must be non-lactating and practicing a reliable method of and have a negative urine pregnancy test prior to the initiation of the study procedures. Examples of medically acceptable methods for this protocol include oral contraceptive pills, intrauterine device, injection of Depo-Provera, Norplant, contraceptive patch, contraceptive ring, double-barrier methods (such as condoms and diaphragm/spermicide), male partner sterilization, abstinence (and agreement to continue abstinence or to use an acceptable method of contraception, as listed above, should sexual activity commence).

Exclusion criteria

Exclusion Criteria:

  • Planned surgery within the timeframe of the study
  • A current, physical disease or abnormality on the basis of medical history, physical examination, or routine laboratory evaluation that could interfere with study participation or make it hazardous for the subject to do so (e.g., bleeding disorder, pancreatitis, epilepsy, diabetes, liver disease, kidney disease, or cardiomyopathy as determined by history and clinical exam); ALAT or ASAT concentration greater than 3 times the (ULN), or direct above the ULN. (Note-abnormal laboratory tests during screening may be repeated once).
  • Chronic or episodic painful conditions that could require opioid medications for pain control
  • History of seizure disorder (excluding childhood febrile seizures)
  • History of allergy or other serious adverse event due to treatment with XR-NTX
  • Current psychotic disorder (bipolar, schizophrenia, major depression with suicidal ideation, or psychotic features) identified by clinical examination or the structured interview that could interfere with study participation or make it hazardous for the subject.
  • Current diagnosis of any drug use disorder other than alcohol, nicotine, or cannabis or a urine drug screen that is positive for benzodiazepines, opioids, amphetamines, cocaine or barbiturates.
  • Current treatment with a psychotropic, anticonvulsant, opioid, anticoagulant or AUD treatment medication (i.e., naltrexone, acamprosate, disulfiram, topiramate, gabapentin, varenicline, or baclofen)
  • Receipt of any experimental medication within the past 30 days
  • In need of medical detoxification from alcohol
  • Subjects cannot have been mandated by court for alcohol or drug abuse treatment or have pending legal proceedings that could result in incarceration within 6 months of enrollment.
  • Homicidal or other behavioral disturbance that requires immediate clinical attention
  • Judged by the principal investigator or his designee to be an unsuitable candidate for study participation
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    XR-NTX 380 mg, intramuscular injection

    Subjects will receive an injection of XR-NTX 380 mg (4 mL) repeated once after 4 weeks.

    Drug: XR-NTX 380 mg, intramuscular injection · Behavioral: Medical Management

  • Placebo comparator
    Inactive placebo intramuscular injection

    Subjects will receive a placebo injection repeated once after 4 weeks.

    Behavioral: Medical Management · Drug: Placebo intramuscular injection

Interventions

  • DrugXR-NTX 380 mg, intramuscular injection

    Two doses of XR-NTX 380 mg, intramuscular injection.

    Also known as: Vivitrol naltrexone for extended-release injectable suspension

  • BehavioralMedical Management

    All subjects will receive 8 weeks of medical management (Pettinati et al. 2004) will support subjects' efforts to reduce or stop their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the subject's drinking, and make recommendations to follow until the next visit. Men will be advised to consume no more than 3 drinks 4 times per week; women will be advised to consume no more than 2 drinks 4 times per week.

  • DrugPlacebo intramuscular injection

    Two doses of XR-NTX 380 mg, intramuscular injection.

    Also known as: Inactive placebo

06

What researchers measure

Primary outcomes

  1. Frequency of heavy drinking days by medication group (timeline follow back calendar).

    The number of Heavy Drinking Days during 8 weeks of treatment in the Naltrexone and placebo groups.

    Time frame: 8 weeks

Secondary outcomes

  1. Frequency of drinking days, and drinks/drinking day by medication group (timeline follow back calendar).

    The number of Drinking Days, drinks/drinking day by medication group during 8 weeks of treatment in the Naltrexone and placebo groups.

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Jul 2027, 64 months after the start.

Of 24 phase 4 interventional studies under Alcoholism, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 83. This study's planned 64 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2021
First posted
Aug 31, 2021
StartActual
Mar 7, 2022
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2028
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05028062
Collaborators
Alkermes, Inc.
Responsible party
Sponsor
First posted
Aug 31, 2021
Start date
Mar 7, 2022
Primary completion
Jul 2027 (estimated)
Completion
Jul 2028 (estimated)
Last update
Jan 20, 2026

Study contacts

Timothy S Pond, MPH
Contact
timpond@pennmedicine.upenn.edu
215-746-1959
Rachel Weyl, BS
Contact
rachel.weyl@pennmedicine.upenn.edu
215-746-1902
Henry R Kranzler, MD
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion